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Abstract
Background: Suboptimal antiretroviral therapy (ART) adherence and disengagement in care present significant public health
challenges because of the increased probability of HIV transmission. In the United States, men who have sex with men (MSM)
continue to be disproportionately affected by HIV, highlighting a critical need to engage high-risk MSM living with HIV who
are not engaged or retained in care.
Objective: The aim of the study was to assess the feasibility of at-home blood self-collection and laboratory quantification of
HIV-1 RNA viral load (VL) to report laboratory-based VL outcomes and compare self-reported and laboratory-reported VL
Methods: Between 2016 and 2017, 766 US HIV-positive MSM enrolled in a Web-based behavioral intervention were invited
to participate in an at-home dried blood spot (DBS) collection study using HemaSpot-HF kits (Spot On Sciences, Inc, Austin,
TX) for laboratory-quantified VL.
Results: Of those invited to participate, 72.3% (554/766) enrolled in the DBS study. Most (79.2%, 439/554) men enrolled
reported attempting to collect their blood, 75.5% (418/554) of participants mailed a DBS specimen to the research laboratory,
and 60.8% (337/554) had an adequate blood sample for VL testing. Of the 337 specimens tested for VL by the laboratory, 52.5%
(177/337) had detectable VL (median: 3508 copies/mL; range: 851-1,202,265 copies/mL). Most men (83.9%, 135/161) who
returned a DBS specimen with laboratory-quantified detectable VL self-reported an undetectable VL during their last clinical
visit.
Conclusions: Home collection of DBS samples from HIV-positive MSM is feasible and has the potential to support clinical
VL monitoring. Discrepant laboratory HIV-1 RNA values and self-reported VL indicate a need to address perceived VL status,
especially in the era of treatment as prevention. Most participants were willing to use an at-home DBS kit in the future, signaling
an opportunity to engage high-risk MSM in long-term HIV care activities.
(JMIR Public Health Surveill 2018;4(4):e10847)   doi:10.2196/10847
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Introduction
Background
Suboptimal antiretroviral therapy (ART) adherence and
intermittent engagement in care present significant public health
challenges because of the increased probability of HIV
transmission resulting from high HIV-1 RNA viral load (VL)
[1-5]. It is critical to assess strategies to monitor VL among
individuals living with HIV who are not consistently ART
adherent. In the United States, men who have sex with men
(MSM) continue to be disproportionately affected by HIV; in
2016, MSM accounted for 66.79% (26,570/39,782) of all HIV
diagnoses and 82.69% (26,570/32,131) of diagnoses among
men [1]. Among US MSM known to be living with HIV in
2014, 74.07% (265,280/358,151) had received any care, 57.66%
(206,523/358,151) were retained in care, and 61.16%
(219,043/358,151) of those in care achieved viral suppression,
although engagement in care and viral suppression were lowest
among younger MSM and black MSM [6,7]. Research and
program initiatives have aimed to increase both the number of
MSM who are tested and who engage in care after an HIV
diagnosis [8-10]. At-home rapid HIV self-testing has provided
another option for MSM to be tested, and studies have shown
that MSM are willing to self-test rather than use traditional
testing sites because of stigma, privacy-related concerns, and
the ability to test at any time [11-13]. There is a similar need
for VL self-testing or sample collection approaches to be
developed for MSM living with HIV that can support traditional
HIV clinical care and increase the proportion of virally
suppressed MSM living with HIV.
The Mailed-Spot (M-Spot) study assessed the feasibility of
home self-collection of dried blood spot (DBS) specimens for
laboratory quantification of VL among US white, black, and
Hispanic MSM living with HIV who participated in a
Web-based behavioral intervention [14]. Because MSM
commonly use the Internet and smartphone apps for sexual and
health purposes, Web-based and mobile settings provide an
opportunity for engagement and obtaining biologic specimens
in behavioral research [15-17].
Study Objectives
We report feasibility and VL outcomes among MSM living with
HIV who received a novel DBS collection kit for at-home blood
self-collection and laboratory quantification of VL.
Methods
Study Overview
MSM participating in Sex Positive! (parent study), a national
Web-based behavioral intervention, were invited to take part in
the M-Spot study following completion of the original study.
The parent study’s protocol has been described previously [14].
Briefly, eligible participants in the parent study were (by
self-report) biologically male and identified as a male or
genderqueer; aged 18 years or older; white, black, or Hispanic;
able to read and respond in English; a US resident; HIV-positive;
not virally suppressed (>200 copies/mL) in the past year or
reported past-month suboptimal ART adherence [18]; and had
condomless anal sex with an HIV-negative or unknown status
male partner in the past 6 months.
Ethics Statement
The institutional review board (IRB) at Public Health Solutions
in New York, NY, approved all study procedures. The IRB at
Johns Hopkins University in Baltimore, MD, approved all
laboratory-related procedures. Participants provided consent by
clicking a button at the end of the Web-based consent form to
indicate that they had read the consent page and agreed to
participate. A Certificate of Confidentiality was obtained from
the National Institute of Mental Health to protect the privacy
of participants enrolled in this study.
Participants
For the M-Spot study, men received an email recruitment
solicitation within a week of completing the parent study’s
12-month follow-up survey. The email contained a link that
redirected them to a brief, secure screening survey. Those ever
diagnosed with hemophilia, or who were currently taking
anticoagulation medication, were excluded.
Study Procedures
Consenting participants were mailed a package containing one
HemaSpot-HF device (DBS kit; Spot On Sciences, Inc, Austin,
TX), collection materials (alcohol prep pads, lancets, gauze pad,
and adhesive bandages), an instruction card, and a return
envelope with postage. Men read the instruction card or viewed
a video that demonstrated how to collect their blood and mail
their DBS specimen to the International STD Research
Laboratory at Johns Hopkins University.
After self-collecting a DBS specimen, men completed a brief
Web-based survey (herein referred to as the M-Spot survey),
which inquired about the blood collection process; experience
using the kit (ie, attempts to use the kit, experience using the
lancet, etc); experience with the study materials (ie, did they
watch the video, did they understand the instruction card);
willingness to use a DBS kit in the future; and engagement in
HIV care since the parent study’s 12-month follow-up survey.
After collecting their blood specimen and completing the M-Spot
survey, men mailed their DBS specimen to the research
laboratory.
HemaSpot-HF was developed to address technical issues
associated with using traditional filter cards for DBS collection
[19]. A protective plastic cartridge minimizes the risk of
contamination and contains a desiccant ring to keep the sample
free from moisture. Immediately after blood collection, the
desiccant allows the kit to be closed for shipment. Upon receipt
at the laboratory, DBS specimens were stored for up to 4 months
at 4°C before testing. If a DBS kit was half-filled with blood or
not filled at all, the sample was deemed untestable. Acceptable
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samples were tested in batches corresponding to laboratory
receipt date.
DBS specimens were placed in an Abbott Master Mix Tube
(Abbott Molecular Inc, Des Plaines, IL) containing 1.3 mL of
Abbott mSample Preparation system DBS Buffer (a
research-use-only assay) incubated for 30 min at 55°C with
gentle mixing and placed on the Abbott m2000sp instrument
for sample extraction. The Abbott m2000sp/rt system used an
open-mode protocol for DBS samples [20]. VL results were
reported as “not detected,” if no HIV-1 RNA was detected in
the sample. A qualitative result of “≤832 copies/mL (≤2.92 log
copies)” was reported when fewer than or equal to 832
copies/mL of HIV-1 RNA were detected. Quantitative VL
results were reported when HIV-1 RNA was detectable above
832 copies/mL (2.93 log copies to 7.00 log copies). A lower
limit of quantification was not reported by the manufacturer as
there is a low probability of reproducibility when samples have
viremia ≤2.92 log copies (832 copies/mL). On the completion
of DBS specimen analysis, aggregate results from the study
were emailed to all consenting participants. We did not have
IRB approval to provide individual results to participants.
Survey Measures
The M-Spot survey was designed to assess the feasibility of
collecting a DBS specimen for VL and also to capture HIV care
information that may have occurred between the end of the
parent study and enrollment in the M-Spot study. To reduce
participant’s burden, HIV care questions were only asked if the
participant reported seeing an HIV care provider after
completing the 12-month survey (see Self-Reported Viral Load
Status subsection). M-Spot survey data were merged with data
from the parent study’s screener (herein referred to as screener)
and the parent study’s 12-month follow-up survey (herein
referred to as the parent survey). Demographic measures were
primarily collected from the screener, HIV care and adherence
measures for this analysis were collected from the parent survey,
and DBS feasibility questions were collected from the M-Spot
survey. Median time between the completion of the screener
and the M-Spot survey was 405 days (range: 367-617 days),
and median time between the completion of the parent survey
and the M-Spot survey was 36 days (range: 6-257 days). All
survey data were collected online.
Participant Characteristics
The screener included questions on participant’s age, race and
ethnicity, gender identity, and sex at birth. Recruitment source
was also identified from the screener, based on the recruitment
URL used by the participant. Participants indicated on the parent
survey whether they were diagnosed with HIV in the past year.
The parent survey also obtained updated level of education,
annual income, employment status, and insurance information.
Sexual History
Participants reported number of male anal insertive and receptive
sex partners in the last 3 months on the parent survey. Pull-down
menus listed 0 through 100 partners, 101+ partners, I don’t
know, and prefer not to answer.
HIV Care
To assess engagement in HIV care, men were asked on the
parent survey whether they had a doctor, nurse, or other medical
provider whom they considered to be in charge of their overall
HIV health care. Response options included no, yes, and prefer
not to answer. Participants were also asked on the parent survey
when was the last time they had a health care appointment with
their HIV care provider (last 3 months, 3-6 months ago, 6-9
months ago, 9-12 months ago, more than a year ago, I don’t
know, and prefer not to answer).
Antiretroviral Medication Adherence
Participants were asked on the parent survey about their current
use of antiretroviral medications (yes, no). Among participants
on treatment, past 30-day adherence to ART was assessed using
a 3-item scale [18]. Participants were asked: “In the last 30 days,
on how many days did you miss at least one dose of any of your
HIV medicines?” (0-30 days); “In the last 30 days, how good
a job did you do at taking your HIV medicines in the way you
were supposed to?” (never, rarely, sometimes, usually, almost
always, always); and “In the last 30 days, how often did you
take your HIV medicines in the way you were supposed to?”
(never, rarely, sometimes, usually, almost always, always).
Responses to each question were linearly transformed to a 0 to
100 scale and averaged across all 3 items.
Self-Reported Viral Load Status
The M-Spot survey included items to measure self-reported VL
status at the time of blood collection. Participants indicating an
HIV care visit since the parent survey were asked whether they
had a VL test. Men who reported having a VL test were asked
to estimate the date of their last VL test and to select their most
recent results from the following: My viral load was
undetectable; My viral load was detectable; I don’t know—but
I think I was detectable; and I don’t know—but I think I was
undetectable. Participants reporting My viral load was detectable
or I don’t know—but I think I was detectable were categorized
as having a self-reported detectable VL status. Participants
reporting My viral load was undetectable or I don’t know—but
I think I was undetectable were categorized as having a
self-reported undetectable VL status.
Data on self-reported VL status from participants who did not
report an HIV care visit between the parent survey and the
M-Spot study were obtained from the parent survey; men who
reported a VL test in the past 6 months on the parent survey
were asked to select their most recent results from the following:
My viral load was undetectable, or <200 copies/mL; My viral
load was detectable, or >200 copies/mL; I don’t know—but I
think I was undetectable; and I don’t know—but I think I was
detectable. Using the same strategy as in the M-spot survey,
responses were dichotomized (detectable, undetectable). The
date of the last VL test was not collected on the parent survey.
Time Between Self-Reported Viral Load and Dried Blood
Spot Specimen Collection
The difference between the date of DBS specimen collection
and date of self-reported VL status on the M-Spot or parent
survey was used to estimate the time between a self-reported
VL from a plasma sample (collected during an HIV care visit)
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and a VL laboratory result from a DBS specimen. The calendar
date reported for last VL test in the M-Spot survey was used as
the participant’s self-reported VL date. The parent survey did
not ask participants to report the date of their last VL test. Thus,
for participants who did not visit their HIV care provider in
between the parent study and the M-Spot study, the day they
finished the parent survey was used as a proxy for the
participant’s self-reported VL test date. If participants did not
self-report a VL status on either the M-Spot survey or parent
survey, their self-reported VL status was treated as missing.
Experience Using Dried Blood Spot Kit
Experience using the DBS kit at home was measured through
several questions on the M-Spot survey. Men were asked if they
felt comfortable collecting their own blood sample (yes, no,
prefer not to answer), and they were asked to rate their overall
experience using the HemaSpot-HF device (very easy, easy,
hard, very hard, prefer not to answer). Participants were also
asked to rate their willingness to use a DBS kit in a future study
(very willing, willing, not willing, extremely not willing, prefer
not to answer).
Statistical Methods
We assessed study feasibility by the proportion of participants
who successfully completed various stages: enrollment,
collecting a blood sample, mailing the kit to the laboratory,
laboratory receipt of DBS specimens, and providing a testable
blood sample. Pearson chi-square tests, Fisher exact tests,
independent-sample t-tests, and Mann-Whitney U tests were
used to identify group differences between participants who
enrolled and did not enroll in the study and between participants
who returned a DBS sample with detectable and undetectable
viremia. Data analyses were performed using SAS version 9.4
(SAS Institute, Cary, NC).
Results
Participant Characteristics
From September 2016 to February 2017, an invitation link to
participate in the M-Spot study was sent to 766 men living with
HIV within a week of completing the parent survey (Figure 1,
box A). Of note, 112 men had completed the parent survey
before we received IRB approval and thus were not eligible to
participate in the study. Among recruited men, 86.6% (663/766)
opened the email and clicked on the screener link (Figure 1,
box B). Men who clicked the link were more likely to have
health insurance (93.6% [617/659] vs 88.1% [89/101], P=.04)
and a past 6-month HIV health care visit (92.4% [549/594] vs
83.0% [78/94], P<.01) than men who did not click the link. In
total, 568 men were eligible to participate, 562 consented (Figure
1, box C), and 554 (72.3% [554/766] of those recruited) enrolled
in the study (Figure 1, box D). To enroll, participants had to
provide a mailing address to receive the DBS kit by mail.
Most enrolled participants were white (68.8%, 381/554),
college-educated (61.7%, 341/553), and had a yearly income
of less than US $40,000 (54.9%, 304/554; see Table 1). Median
age was 39 years (range: 19-72 years). Most men (56.1%,
332/542) enrolled in M-Spot had been recruited for the parent
study from a website for men interested in condomless anal sex
with a male partner. Over half (57.8%, 320/554) were employed
full time, and 94.0% (516/549) were insured—half through
public health insurance. Participants self-reported a median of
2 male sexual partners (range: 0-101) in the past 3 months. A
minority of men (19.1%, 105/551) were diagnosed with HIV
in the 12 months before they enrolled in the parent study. On
the basis of participants’ self-report, 91.1% (499/548) were
engaged in HIV care; 93.0% (463/498) had visited their HIV
care provider in the past 6 months; and 93.3% (516/553) were
currently on ART, with a median Wilson adherence score of
88.9% (range: 0%-100%); and 90.8% (456/502) self-reported
an undetectable VL (≤200 copies/mL) from their last clinical
laboratory test. Compared with men who did not enroll in the
M-Spot study, men who enrolled were more likely to have seen
their HIV care provider in the past 6 months (93.0% [463/498]
vs 86.3% [164/190], P=.02) and more likely to report ART use
(93.3% [516/553] vs 89.1% [188/211], P=.05; see Table 1).
Feasibility and Acceptability
Of the 554 men enrolled in M-Spot, 79.2% (439/554) reported
attempting to collect their blood (Figure 1, box E). Some
participants (n=49) requested a second DBS kit; reasons included
difficulties collecting their blood or losing the kit. Of these men,
11 had issues drawing blood with the lancet and attributed this
to callused fingertips. The initial lancet used for this study had
an 18-gauge blade with a 2.3-mm penetration depth. In response
to lancet-related issues, we sent the 11 participants, and all
subsequently enrolled participants, lancets that had a 21-gauge
needle and 2.8-mm penetration depth.
A high proportion (75.5%, 418/554) mailed a DBS specimen
to the laboratory (Figure 1, box F). The laboratory received and
evaluated 413 kits (Figure 1, box G). The median time between
sample collection and specimen receipt was 4 days (range: 1-69
days). Among the kits received, 76 were not analyzed: 65 had
an inadequate amount of blood and were deemed untestable, an
instrument error occurred when processing 7 specimens, and
an internal control error occurred when processing 4 specimens.
In total, 337 kits had a sufficient amount of blood and were
tested (Figure 1, box H).
Among men who returned a DBS specimen to the laboratory
and completed the study survey, 89.8% (326/363) reported
feeling comfortable collecting their blood; 83.6% (306/366)
rated their experience using the DBS kit as “very easy” or
“easy,” and 98.1% (357/364) reported willingness to use an
at-home DBS kit in the future.
Among 115 participants who did not attempt to use the DBS
kit, 105 men received the kit but did not participate (ie, were
lost to follow-up), 7 men withdrew from the study, 2 men never
received the kit, and 1 participant decided not to use the kit after
opening the package. The men who were lost to follow-up or
withdrew were predominantly white (69.6%, 80/115),
college-educated (58.3%, 67/115), earned less than US $40,000
(57.1%, 64/112), and had a lower Wilson ART adherence score
(81% vs 85%; P=.04) than men participating in study activities.
Finally, 15 participants were unable to collect their blood and
did not mail their kit.
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Figure 1. M-Spot study recruitment and participation. M-Spot: Mailed-Spot.
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Table 1. Sociodemographic and behavioral characteristics of recruited participants, by enrollment status (N=766).
P valueIneligible or not enrolled (n=212)Enrolled (n=554)Total (N=766)Characteristics
.10bAge in years (n=765)a, n (%)
44 (20.8)111 (20.1)155 (20.3)18-29
52 (24.5)181 (32.7)233 (30.5)30-39
62 (29.3)159 (28.8)221 (28.9)40-49
42 (19.8)84 (15.2)126 (16.5)50-59
12 (5.7)18 (3.3)30 (3.9)≥ 60
.31bRace (n=766), n (%)
41 (19.3)83 (15.0)124 (16.2)Black
30 (14.2)90 (16.3)120 (15.7)Hispanic
141 (66.5)381 (68.8)522 (68.2)White
.55bEducation (n=763)a, n (%)
15 (7.1)53 (9.6)68 (8.9)High school diploma or less
65 (31.0)159 (28.8)224 (29.4)Some college
81 (38.6)228 (41.2)309 (40.5)College graduate
49 (23.3)113 (20.4)162 (21.2)Professional or graduate degree
.21bIncome (n=743)a, n (%)
52 (25.9)173 (31.9)225 (30.3)<$20,000
51 (25.4)131 (24.2)182 (24.5)$20,000-$39,999
35 (17.4)102 (18.8)137 (18.4)$40,000-$59,999
31 (15.4)80 (14.8)111 (14.9)$60,000-$99,999
32 (15.9)56 (10.3)88 (11.8)≥$100,000
.41bInsured (n=757)a, n (%)
92 (44.2)257 (46.8)349 (46.1)Yes, private health insurance
98 (47.1)259 (47.2)357 (47.2)Yes, public health insurance
18 (8.7)33 (6.0)51 (6.7)No
.95b123 (58.0)320 (57.8)443 (57.8)Employed full time (n=766), n (%)
.44bRecruitment source (n=764)a, n (%)
64 (30.3)170 (30.7)234 (30.6)Mobile phone app
121 (57.4)332 (60.0)453 (53.3)Bareback website
26 (12.3)51 (9.2)77 (10.1)Other sites
.80b190 (90.5)499 (91.1)689 (90.9)Engaged in HIV care (n=758)a, n (%)
.05c188 (89.1)516 (93.3)704 (92.2)Currently on antiretroviral therapy (n=764)a, n (%)
.39a46 (21.8)105 (19.1)151 (19.8)Past year HIV diagnosis (n=762)a, n (%)
.02b,cLast HIV care visit (n=688)a, n (%)
164 (86.3)463 (93.0)627 (91.1)<6 months
22 (11.6)29 (5.8)51 (7.4)6-12 months
4 (2.1)6 (1.2)10 (1.5)>12 months
.18bSelf-reported HIV viral load status (n=673)a, n (%)
161 (94.5)456 (90.8)617 (91.7)Undetectable
10 (5.9)46 (9.2)56 (8.3)Detectable
JMIR Public Health Surveill 2018 | vol. 4 | iss. 4 | e10847 | p.6http://publichealth.jmir.org/2018/4/e10847/
(page number not for citation purposes)
Hirshfield et alJMIR PUBLIC HEALTH AND SURVEILLANCE
XSL•FO
RenderX
P valueIneligible or not enrolled (n=212)Enrolled (n=554)Total (N=766)Characteristics
.88d84.384.684.5Antiretroviral therapy adherence score, mean (n=703)a
.56e10.521.218.3Number of male anal sex partners, last 3 months, mean (n=766)
aDenominators vary because of missing data.
bPearson chi-square test.
cStatistical significance at level P≤.05.
dIndependent-sample t test.
eMann-Whitney U test.
Viral Load Results
Of the 337 specimens tested for VL by the laboratory, over half
(52.5%, 177/337) had detectable VL, whereas 47.5% (160/337)
of participants returned a sample with no detectable HIV-1 RNA
(Figure 2). Of the DBS specimens classified as having a
detectable VL, a total of 99 DBS specimens from participants
had a qualitative result of “≤832 copies/mL (≤2.92 log copies),”
and 78 DBS specimens had a quantitative result of >832
copies/mL. Among the DBS specimens with a quantitative VL
(n=78), the overall median VL was 3508 copies/mL
(interquartile range, IQR: 1349-21,754 copies/mL). When
stratified into different levels of viremia, 9 specimens had
detectable viremia between 833 and 999 copies/mL (median:
891 copies/mL; IQR: 870-955 copies/mL), 43 specimens were
between 1000 and 9999 copies/mL (median: 1995 copies/mL;
IQR: 1349-4542 copies/mL), and 26 specimens had viremia
≥10,000 copies/mL (median: 46,823 copies/mL; IQR:
22,264-144,865 copies/mL; see Figure 2). Compared with
participants who returned a DBS specimen with detectable
viremia, men who returned a DBS specimen with undetectable
viremia were significantly more likely to be employed full-time
(63.1% [101/160] vs 52.5% [93/177], P=.05), report a recent
HIV diagnosis (<1 year; 23.1% [37/160] vs 12.5% [22/176],
P=.01), be engaged in HIV care (96.9% [155/160] vs 86.4%
[152/176], P<.01), and be currently on ART (98.8% [158/160]
vs 88.6% [156/176], P<.01; see Table 2).
Figure 2. Participant laboratory HIV-1 RNA results, n=337.
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Table 2. Characteristics of participants who provided a testable dried blood spot specimen, by HIV-1 RNA viral load status (n=337).
P valueUndetectable HIV-1 RNAa, (n=160)Detectable HIV-1 RNAa, (n=177)Total (n=337)Characteristics
.28bAge in years (n=337), n (%)
35 (21.9)34 (19.2)69 (20.5)18-29
61 (38.1)55 (31.1)116 (34.4)30-39
36 (22.5)55 (31.1)91 (27.0)40-49
28 (17.5)33 (18.6)61 (18.1)≥ 50
.99bRace (n=337), n (%)
19 (11.9)22 (12.4)41 (12.2)Black
27 (16.9)30 (17.0)57 (16.9)Hispanic
114 (71.3)125 (70.6)239 (70.9)White
.05b,c101 (63.1)93 (52.5)194 (54.6)Employed full-time (n=337), n (%)
.60bInsured (n=333)d, n (%)
79 (50.3)79 (44.9)158 (47.5)Yes, private health insurance
69 (44.0)85 (48.3)154 (46.3)Yes, public health insurance
9 (5.7)12 (6.8)21 (6.3)No
.01b,c37 (23.3)22 (12.5)59 (17.6)Past year HIV diagnosis (n=335)d, n (%)
.001b,c155 (96.9)152 (86.4)307 (91.4)Engaged in HIV care (n=336)d, n (%)
.60eLast HIV care visit (n=307)d, n (%)
146 (94.2)140 (92.1)286 (93.2)<6 months
8 (5.2)9 (5.9)17 (5.5)6-12 months
1 (0.7)3 (2.0)4 (1.3)>12 months
<.001b,cSelf-reported HIV viral load status (n=316)d, n (%)
149 (96.1)135 (83.9)284 (89.9)Undetectable
6 (3.9)26 (16.2)32 (10.1)Detectable
<.001b,c158 (98.8)156 (88.6)314 (93.5)Currently on ARTf (n=336)d, n (%)
.33g86.584.485.5ART adherence score, mean (n=313)d
.63h22.929.826.5Number of male anal sex partners (mean),
last 3 months (n=337)
aIndividuals categorized as having a detectable HIV-1 RNA include participants with a quantitative result >832 copies/mL or qualitative result ≤832
copies/mL.
bPearson chi-square test.
cStatistical significance at level P≤.05.
dDenominators vary because of missing data.
eFisher exact test.
fART: antiretroviral therapy.
gIndependent-sample t test.
hMann-Whitney U test.
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Figure 3. Participant self-reported viral load status, by laboratory HIV-1 RNA result, n=316.
We compared participants’ laboratory HIV-1 RNA result with
their most recent self-reported VL. Among participants who
returned a testable DBS specimen, 93.8% (316/337) also
self-reported their VL in the M-Spot survey or the parent survey.
Among the 316 DBS samples, 284 self-reported having an
undetectable VL and 32 self-reported having a detectable VL.
Among men with both laboratory and self-reported VL data,
44.6% (141/316) had a discrepant laboratory HIV-1 RNA result
and self-reported VL status (Figure 3).
Of note, 83.9% (135/161) of the men who returned a DBS
specimen with a detectable HIV-1 RNA result self-reported that
they had an undetectable VL at their last clinical visit (Table
2). Among men self-reporting an undetectable VL, those living
with HIV for >1 year at the start of the parent study were more
likely to have a discrepant self-reported VL and a
laboratory-quantified VL (88.2% [119/135] vs 77.0% [114/148];
P=.01). However, those who self-reported being engaged in
care were less likely to have discrepancies between their
self-reported VL and laboratory-quantified VL compared with
those who self-reported not being engaged in care (91.1%
[123/135] vs 97.3% [145/149]; P=.02).
Median time between a discrepant self-reported VL and a
laboratory-quantified VL was 22 days. Median time between
concordant self-reported VL and a laboratory-quantified VL
was 25 days. Different proportions of discrepant self-reported
VL were observed when the HIV-1 RNA results from the DBS
specimens were disaggregated: 96.2% (101/105) of men with
a laboratory HIV-1 RNA result <1000 copies/mL, 76.9% (30/39)
of men with a laboratory HIV-1 RNA result <10,000, and 23.5%
(4/17) of men with a laboratory HIV-1 RNA result ≥10,000
copies/mL had a discrepant self-reported VL (Figure 3
—indicated in red). Finally, an additional 21 participants
returned a testable DBS specimen but did not self-report their
VL in the survey. Of these men, 16 returned a sample with
detectable viremia; of these, 13 men had a VL >1000 copies/mL
(median: 20,893 copies/mL; range: 3467-154,881 copies/mL).
Discussion
Principal Findings
This study assessed the feasibility and acceptability of an
at-home DBS collection kit for laboratory VL quantification
from US MSM living with HIV who had previously reported
suboptimal ART adherence or a detectable VL. To our
knowledge, this is the first DBS home collection study from a
Web-based sample of MSM living with HIV who mailed a DBS
specimen to a laboratory for VL quantification. Feasibility was
demonstrated at multiple study stages: 72.3% (554/766) of
recruited men enrolled; 79.2% (439/554) of enrolled men
attempted to collect a blood sample; 75.5% (418/554) mailed
their DBS specimen to the laboratory and were received by the
laboratory; and 60.8% (337/554) provided a testable blood
sample. Among participants who returned a kit with a testable
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blood sample, 52.5% (177/337) had a detectable VL. Of
significance, 83.9% (135/161) of DBS specimens with a
detectable VL were from men who self-reported that they had
an undetectable VL at their last clinical visit. These results
suggest that at-home DBS collection for laboratory-quantified
VL is both feasible and acceptable and may serve as a VL
monitoring platform for MSM.
Our results support the findings of other studies with respect to
the acceptability of self-collecting biologic specimens[21-23]
and the willingness of MSM to self-collect blood samples for
HIV testing [24-28]. The traditional DBS sampling using
Guthrie cards or filter paper disks has been used for more than
40 years [29-31] and is now common in epidemiologic studies
[32,33]. DBS sampling has been used in nonclinical settings
for quantifying VL to identify acute and undiagnosed HIV
infections [34,35]. However, DBS collection in nonclinical
settings for VL quantification in known HIV-positive cohorts
has largely been unexplored until now.
Results from 3 recent studies [36-38] prompted the Centers for
Disease Control and Prevention and the National Institute of
Allergy and Infectious Diseases to declare that people on ART
who have an undetectable VL have no risk of transmitting the
virus to HIV-negative partners [39,40]. To prevent further HIV
transmission, individuals diagnosed with HIV must be engaged
in care, take ART as prescribed, and achieve and maintain viral
suppression [36,41]. The “Undetectable=Untransmittable”
campaign has the potential to promote the benefits of HIV
treatment, help alleviate stigma, and prevent further HIV
transmission [42]. However, for the campaign to be effective,
an individual’s perceived undetectable VL status must accurately
match their actual VL status. The high proportion of individuals
with a discrepant laboratory HIV-1 RNA result and self-reported
VL status reported in this study indicates that men either
incorrectly perceived or falsely reported their actual VL status.
A recent study of young MSM and transgender women living
with HIV [43] similarly reports discrepant self-reported VL
survey data with laboratory-based and electronic medical record
VL measurements; approximately a third of participants had
discrepant laboratory-measured VL and a self-reported VL
status. Our study reports a much higher proportion (84% vs
34%) of men with discrepant VL data with differences likely
because of 2 disparate study populations with different age and
racial and ethnic distributions and recruitment methodologies.
We echo the authors’ concerns that discrepancies between
self-reported and laboratory VL data have significant
ramifications for continued HIV transmission, validity of
epidemiological studies (eg, data misclassification), and the
success of public health campaigns. Furthermore, inaccurate
perception of one’s VL status may have potential consequences
for partner-seeking behaviors among HIV-positive MSM who
believe that they are undetectable when they are not.
Although most men returned a DBS specimen with a testable
blood sample, some participants experienced issues collecting
their blood at home. We estimate that about 15% to 20% of
participants had difficulties with the lancets provided with the
DBS kit based on our email and phone communication with the
participants. In addition, some reported difficulties depositing
blood drops into the middle of the application surface, which
prevented them from getting enough blood on the absorbent
paper. Participants experiencing issues often requested a second
kit (where we provided a different lancet with a deeper
penetration depth), did not return their kit to the laboratory, or
returned a kit to the laboratory with little or no blood. Future
studies should anticipate possible specimen self-collection issues
or issues with study materials such as lancets. Addressing these
issues will likely increase the feasibility of at-home specimen
collection.
Novel interventions, devices (eg, Food and Drug
Administration–approved home VL test), and service delivery
options (eg, sharing DBS VL laboratory results with a patient’s
provider) must be developed to increase the number of
individuals who are retained in care and who achieve and
accurately perceive their current VL status. An individual’s VL
is dynamic and viral “blips” can occur throughout the long-term
treatment of HIV because of fluctuations in ART adherence or
concurrent illnesses [44-47]. Individuals with a history of
intermittent HIV care or detectable viremia may be more
inclined to reengage in care or improve ART adherence, if they
know they have a detectable (laboratory-quantified) VL from
an at-home self-collected specimen; future studies should assess
this, as well as whether there are clinical benefits with more
frequent VL monitoring in between clinical visits from samples
collected outside of clinical settings.
Limitations
A few study limitations should be acknowledged. First, with
respect to our email recruitment approach, it is possible that
some participants never saw the email in their inbox or spam
folder. Second, 20.8% (115/554) of enrollees did not complete
study activities; participants who withdrew or were lost to
follow-up had a lower Wilson ART adherence score than those
who attempted or completed study activities. It is possible that
these participants chose not to collect their blood sample after
reading the instructions, or they never opened the DBS package
with study materials. It is also possible that participants who
reported suboptimal ART adherence did not want to provide a
blood sample that would show a detectable VL. Third, the study
population was recruited from a sample of men who successfully
completed a 12-month Web-based intervention. Perhaps these
participants are more likely to complete a study such as M-Spot
compared with other populations. Different study participation
rates may be observed when collecting DBS specimens from
other populations. Fourth, we did not collect a calendar date for
the most recent VL test on the parent survey, limiting our ability
to accurately estimate the time between an individual’s plasma
VL test result and DBS VL test result.
As with most DBS studies, there is concern about the correlation
between a DBS specimen and laboratory result from a VL test
from a plasma sample collected in a clinical setting. Several
studies [48-50] have documented the high correlation between
VL measurements obtained from DBS samples and those
obtained from plasma, as well as the stability of samples stored
under different conditions and for different time frames. In
addition, stability of HIV serological markers in samples
collected using the HemaSpot device has been reported and
compared with DBS samples collected using the traditional
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Whatman 903 cards [51]. Similarly, studies assessing the
performance of the Abbott Real-Time HIV-1 assay, used for
this study, have also reported a high correlation between VL
measurements from DBS and plasma samples, with 99.4% of
cases differing by <1.0 log copies in one study [52], and a mean
difference of 0.29 log copies in another [53]. The Abbott assay
and extraction method have been updated and improved
frequently; this study used the most up-to-date open mode
protocol available from the manufacturer. Dize et al performed
validation of DBS specimens collected using HemaSpot devices
compared with plasma samples [54]. Concordance analysis
showed 100% agreement between samples with VL ≥1000
copies/mL and 86% agreement between samples with VL <1000
copies/mL. Finally, we acknowledge the possibility that
intracellular nucleic acid contribution at low levels of viremia
may explain our DBS specimen laboratory results and the
discordance between self-reported VL status and DBS specimen
VL results. Other studies have reported false-positive rates
ranging from 6% to 13% in which DBS samples yielded
detectable VL, whereas the plasma sample had undetectable
VL, with the discrepancy attributed to a possible contribution
of intracellular RNA that might be present in white blood cells
in whole blood [55-58]. However, it is unlikely that intracellular
nucleic acid led to misclassification of VL results for participants
who had high HIV VL results from their DBS specimen. Further
research is needed to identify the extent to which intracellular
nucleic acid influences VL results from DBS specimens
collected using the HemaSpot-HF device, especially in those
with low detectable HIV VL levels.
Conclusions
Despite these limitations, findings from this study highlight the
feasibility and acceptability of HIV-1 RNA quantification of
home-collected DBS samples from MSM living with HIV.
Individuals with a history of suboptimal ART adherence and/or
detectable viremia, such as those in this study, may benefit from
at-home VL monitoring as a tool to augment engagement in
HIV care. Home collection of DBS for VL could be utilized as
a monitoring tool in between clinical visits for patients who
struggle with adherence. Research on complementary systems
of clinical care should be expanded and further studied,
especially in the era of treatment as prevention.
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